Registry for systemic treatments of alopecia areata

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter prospective registry aims to assess the effectiveness, safety, and long-term outcomes of systemic treatments for alopecia areata, alopecia totalis, and alopecia universalis. It focuses on patients with moderate-to-severe forms of the condition who require more extensive therapies beyond localized treatments. By collecting real-world data on the utilization of these systemic therapies, the registry seeks to provide valuable insights that can inform evidence-based clinical management for affected patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with alopecia areata;
* Starting/using a systemic treatment for alopecia areata;
* Informed consent for registry participation obtained from patient and/or caretaker.

Exclusion Criteria:

* Not sufficiently capable of understanding the Dutch language;
* Not willing to participate.

Where it's running

• Erasmus University Medical Center
  Rotterdam, Netherlands Recruiting

Study contacts

• Study coordinator: DirkJan Hijnen, MD, PhD
• Email: d.hijnen@erasmusmc.nl
• Phone: 0031 10 704 01 10

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Microbiota transplant to treat hair loss from alopecia areata

  This will try a short course of antibiotics followed by an oral microbiota transplant to see if adults with moderate-to-severe alopecia areata can regrow hair.

  Recruiting Phase 2 University of Minnesota · Minneapolis, Minnesota · NCT06747611

• Alopecia Areata: looking at ferroptosis markers in blood

  This study tests whether levels of GPX4 and MDA in blood differ between people with alopecia areata and healthy controls.

  Recruiting Istanbul Training and Research Hospital · Istanbul, Cerrahpasa Mahallesi · NCT07733063

• Treatment of severe alopecia areata in children using baricitinib

  This study is testing if the medication baricitinib can help children aged 6 to under 18 with severe alopecia areata by seeing how well it works and if it’s safe over a long period.

  Recruiting at 99 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 126 other locations · NCT05723198

• Portable scalp cooling system to prevent hair loss during chemotherapy

  This study is testing if a portable cooling device can help women with early-stage breast cancer keep their hair while undergoing chemotherapy.

  Recruiting at 2 sites Cooler Heads Care Inc. · Tucson, Arizona and 1 other locations · NCT05484973

• Which works better for patchy hair loss: steroid injections or microneedling with steroid cream?

  This trial tests whether injecting triamcinolone into the skin or using microneedling with topical triamcinolone helps people with alopecia areata regrow hair more effectively.

  Recruiting Phase 4 Dow University of Health Sciences · Karachi, Sindh · NCT07926711

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.